Tumour	B-Cancer
-	O
specific	O
distribution	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
supports	O
a	O
pathogenetic	O
role	O
in	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
.	O

The	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancers	I-Cancer
remains	O
elusive	O
.	O

Direct	O
involvement	O
of	O
BRCA1	O
in	O
the	O
development	O
of	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
is	O
suggested	O
by	O
the	O
finding	O
that	O
the	O
BRCA1	O
promoter	O
region	O
CpG	O
island	O
is	O
methylated	O
in	O
a	O
proportion	O
of	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancers	I-Cancer
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
incidence	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
in	O
tumours	B-Cancer
in	O
which	O
loss	O
of	O
BRCA1	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
(	O
breast	B-Cancer
and	O
ovarian	B-Cancer
carcinomas	I-Cancer
)	O
with	O
the	O
incidence	O
in	O
tumours	B-Cancer
in	O
which	O
BRCA1	O
is	O
unlikely	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
.	O

Promoter	O
region	O
hypermethylation	O
was	O
significantly	O
more	O
common	O
(	O
P	O
<	O
0	O
.	O
008	O
)	O
in	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
(	O
6	O
/	O
38	O
tumours	B-Cancer
methylated	O
)	O
than	O
in	O
colon	B-Cancer
cancer	I-Cancer
(	O
0	O
/	O
35	O
tumours	B-Cancer
methylated	O
)	O
or	O
in	O
leukaemias	B-Cancer
(	O
0	O
/	O
19	O
samples	B-Cancer
methylated	O
)	O
.	O

The	O
restriction	O
of	O
BRCA1	O
promoter	O
region	O
hypermethylation	O
to	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
is	O
consistent	O
with	O
a	O
pathogenetic	O
role	O
of	O
BRCA1	O
promoter	O
methylation	O
in	O
these	O
tumours	B-Cancer
.	O

We	O
suggest	O
that	O
the	O
rarity	O
of	O
observed	O
BRCA1	O
mutations	O
in	O
sporadic	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
is	O
due	O
to	O
the	O
greater	O
likelihood	O
of	O
BRCA1	O
inactivation	O
by	O
non	O
-	O
mutational	O
mechanisms	O
such	O
as	O
methylation	O
.	O

